Related Experiment Video
Updated: Aug 15, 2026
Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells
Published on: February 27, 2020
Differential gene expression of sulindac-treated human breast epithelial cells
1Biology Department, Brookhaven National Laboratory, Upton, NY 11973, USA. droy@bnl.gov
Abstract:
Breast cancer is the most common malignancy and the second major cause of cancer-related deaths among women in the United States. Recent advances in the molecular genetics of breast cancer have identified various genes associated with tumorigenesis. There is evidence that non-steroidal anti-inflammatory drugs, e.g. sulindac, have some anti-proliferative effects on various tumors involving altered p53 function. Most of these studies have been performed with various human colon carcinoma cell lines and few of them focus on non-malignant proliferative human mammary epithelial cell lines. Therefore, the present study was undertaken to analyze the differentially expressed genes of the p53 signaling pathway by means of a gene array for the immortalized human breast epithelial cell line, MCF-10F, treated with sulindac. Out of the total 96 genes, only 17 were altered by the drug treatment. Among these 17 genes, 6 showed significant alteration (Q > 2.0), whereas 11 genes showed moderate alterations. Altered genes included BRCA1 associated protein-1 [ubiquitin carboxy-terminal hydrolase (bap1)]; cell division cycle 2, G1 to S and G2 to M [cdk1(cdc2)]; and DNA-damage-inducible transcript 1 (gadd45), which were down-regulated. However, N-myc gene 1 (rtp), promyelocytic leukemia (pml), and nuclear factor of kappa-light polypeptide gene enhancer in B-cell 3 and p65 [avian (rel A)] were up-regulated. Northern blot analysis confirmed some of these alterations. The alteration of p53 signaling pathway gene markers by sulindac treatment can give us valuable information about the response to drug treatments in a proliferative cell population.
Insights
Sulindac, a non-steroidal anti-inflammatory drug, alters the p53 signaling pathway in human breast cells. This study identifies specific gene expression changes, offering insights into drug responses for breast cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Breast cancer is a leading cause of death in women, with molecular genetics revealing key tumorigenesis genes.
- Non-steroidal anti-inflammatory drugs, like sulindac, show anti-proliferative effects on tumors with altered p53 function.
- Limited research exists on sulindac's effects on non-malignant human mammary epithelial cells.
Purpose of the Study:
- To investigate the differential gene expression in the p53 signaling pathway of immortalized human breast epithelial cells (MCF-10F) treated with sulindac.
- To identify specific genes within the p53 pathway that are modulated by sulindac exposure.
- To provide insights into the molecular mechanisms underlying sulindac's potential anti-cancer effects.
Main Methods:
- Utilized gene array technology to analyze the expression of 96 genes in the p53 signaling pathway.
- Treated immortalized human breast epithelial cell line MCF-10F with sulindac.
- Confirmed gene expression alterations using Northern blot analysis.
Main Results:
- Sulindac treatment altered 17 out of 96 genes in the p53 signaling pathway.
- Six genes showed significant alterations (Q > 2.0), and 11 showed moderate alterations.
- Down-regulated genes included bap1, cdk1(cdc2), and gadd45; up-regulated genes included rtp, pml, and rel A.
Conclusions:
- Sulindac significantly alters the expression of key genes within the p53 signaling pathway in human breast epithelial cells.
- These findings contribute to understanding the molecular targets of sulindac in a proliferative cell context.
- Modulation of p53 pathway genes by sulindac may inform future therapeutic strategies for breast cancer.
